Keywords
How to Cite
Abstract
Atwo major metabolites would bereliably detected in 80% of the urinesamples. Five subjects received 5mg and fifteenreceived 2mg for 5 days of observed dosing with urine sampled on days 1, 4 and5. OPC3373 was found in 93% of the samples compared to 50% for aripiprazoleand 8% for dehydroaripiprazole. Aripiprazole serum samples on days 1 and 5 weresimilar indicating that steady state had been achieved. This information is consistentwith the subjects being adherent to their prescribed dosing at study entry. In conclu-sion, urine levels of OPC3373 appear to be the most reliable marker for monitoring compliance with aripiprazole.
References
VelliganDI, Lam F, Ereshefsky L, Miller AL. Psychopharmacology:Perspectives on medication adherence and atypical antipsychotic medications. Psychiatr Serv. 2003; 54: 665-667.
WeidenP, Glazer W. Assessment and treatment selection for “revolving door” inpatients with schizophrenia. Psychiatr Q. 1997; 68: 377-392.
ValensteinM, Copeland LA, Owen R, Blow FC, Visnic S. Adherence assessments and the use of depot antipsychotics in patients with schizophrenia. J Clin Psychiatry. 2001; 62: 545-551.
DolderCR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medication adherence: is there a difference between typical and atypical agents?Am J Psychiatry. 2002; 159: 103-108.
GrymonpreRE, Didur CD, Montgomery PR, Sitar DS. Pill count, self-report, and pharmacy claims data to measure medication adherence in the elderly. Ann Pharmacother. 1998; 32: 749-754.
HaynesRB, Introduction. In: Sackett DI, Taylor DW, eds. Compliance in Health Care Baltimore, MD: Johns Hopkins University Press; 1979.
CramerJA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv. 1998; 49: 196-201.
VelliganDI, Lam YW, Glahn DC, Barrett JA, Maples NJ, Ereshefsky L, et al. Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophr Bull. 2006; 32: 724-742.
VelliganDI, Wang M, Diamond P, Glahn DC, Castillo D, Bendle S, et al.Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiatr Serv. 2007; 58: 1187-1192.
10.MallikaarjunS, Shoaf SE, Boulton DW, Bramer SL. Effects of hepaticor renal impairment on the pharmacokinetics of aripiprazole. ClinPharmacokinet. 2008; 47: 533-542.
11.DeLeonA, Patel NC, Crismon ML. Aripiprazole: a comprehensivereview of its pharmacology, clinical efficacy, and tolerability. Clin
Ther. 2004; 26: 649-666.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright (c) 2025 Food Additives and Contaminants
